• Platelet phenotypes can be modified by lentiviral transduction of hematopoietic stem cells.
Introduction
Platelets are anuclear cell fragments in the blood with essential functions in hemostasis, inflammation and vascular repair. They are released from megakaryocytes (MKs), which differentiate from hematopoietic stem cells (HSCs) in the bone marrow (BM). Knowledge about megakaryopoiesis and platelets is mostly derived from murine models. Knockout/transgenic approaches have been widely used for this purpose [1] [2] [3] . In the field of MK and platelet biology, the lineage-specific expression of Cre by the Correspondence: Ute Modlich, Research Group for Gene Modification in Stem Cells, LOEWE Center for Cell and Gene Therapy Frankfurt, Paul-Ehrlich-Institute, 63225 Langen, Germany. Tel.: +49 6103 77 7500; fax: +49 6103 77 1234. E-mail: Ute.modlich@pei.de platelet factor 4 (Pf4) promoter is often applied, allowing the deletion of the gene of interest in MKs at early stages [4] . However, knockout or transgenic mouse models rely on the development of new mouse strains, which can be tedious and time consuming. An alternative approach is the genetic modification of HSCs by lentiviral vector transduction and subsequent transplantation into recipient mice. As these vectors stably integrate into the genome, they guarantee the long-term expression of a transgene in the hematopoietic system. The concept of retro/lentiviral gene transfer has also proven to be successful in clinical gene therapy for the treatment of monogenetic diseases with hematological phenotypes such as primary immunodeficiencies [5, 6] . Retroviral vectors for specific expression in platelets via modification of HSCs are also of interest for gene and cell therapies targeting proteins to platelets. This has been investigated for the correction of platelet disorders [7, 8] or the expression of clotting factors in platelets to treat hemophilia A and B [9] [10] [11] [12] [13] [14] .
To study megakaryopoiesis or to modify platelets by lentiviral gene transfer, restricted expression to MKs is important to avoid off-target effects due to expression in other hematopoietic lineages. This can be achieved by the use of lineage-specific promoters in lentiviral vectors, which restrict the expression after vector integration, as has already been shown, for example, in myeloid cells [15] , macrophages [16] or B cells [17] . The often-applied MKspecific promoters are derived from the human integrin subunit alpha 2b (CD41), human glycoprotein (GP)Iba (CD42b) or rat Pf4 genes. However, recent analyses of the Pf4 promoter activity in the Pf4-Cre mouse have raised concerns about the specificity of expression from this promoter [18] . Further studies highlighted the close relationship between MKs and HSCs [19, 20] and the expression of CD41 in a subset of HSCs with the lineage marker-negative, Sca-1 and c-Kit-positive (LSK) cell surface phenotype [21] , questioning the usefulness of the alpha 2b promoter in restricting expression to megakaryocytes and platelets.
In this study, we generated self-inactivating lentiviral vectors for MK lineage-specific expression by the use of MK-specific promoter fragments. Specificity and efficiency of the vectors were analyzed in vitro and in BM transplantation assays in vivo. New lentiviral vectors with faithful expression in MKs will be a valuable tool that allows rapid screenings of multiple genes during megakaryopoiesis.
Materials and methods

Lentiviral vectors
MK-specific promoters were amplified from human/ mouse genomic DNA by PCR and inserted into the lentiviral vector RRL.PPT.SF.eGFP.pre (kindly provided by A. Schambach, Hannover Medical School [22] ): 595 bp human glycoprotein 1b alpha promoter (GPIba, -265 to +330) [23] [24] [25] , 1222 bp murine platelet factor 4 promoter (mPf4,-1074 to +148) [26] , 726 bp human glycoprotein 6 (hGP6, -697 to +29) [27] , 351 bp short version of the hGP6 promoter (hGP6s, -322 to +29) [23] , 794 bp human glycoprotein 9 promoter (hGP9, -782 to +12), 676 bp mGP9 (-627 to +49) [28] . As controls, a lentiviral vector with the human phosphoglycerate kinase promoter (hPGK, À436 to +76, vector RRL.PPT.PGK.eGFP.pre) and the gammaretroviral long terminal repeat (LTR)-vector RSF91.eGFP.pre were used [22] . Vectors expressed GFP (green fluorescent protein) or the murine myeloproliferative leukemia oncogene (Mpl).
Generation of lentiviral vector supernatants
First, 5 9 10 6 293T cells were seeded in 10-cm plates in Dulbecco's Modified Eagle Medium (DMEM) medium, 10% fetal calf serum (FCS), 1% glutamine, 1% penicillin/streptomycin and 20 mM HEPES and transfected by calcium-phosphate transfection with 10 lg of vector-plasmid, 10 lg gag/pol plasmid (pCDA3.GP.4XC plasmid), 1.5 lg plasmid encoding the vesicular stomatitis virus G glycoprotein (VSV-G) envelope (PMD.G plasmid) and 5 lg Rev-encoding plasmid in DMEM medium supplemented with 25 lM of chloroquine. Supernatants were collected after 36 and 48 h, concentrated by ultra-speed centrifugation at 80 000 g 9 2 h, resuspended in StemSpan medium (Stem Cell Technologies, K€ oln, Germany) and stored at À80°C. Vector titers were determined by transduction of SC1 cells in serial dilutions followed by flow cytometry or vector copy number detection by qPCR (in case of MK-specific vectors).
Isolation and transduction of murine lineage markernegative (lin À ) BM cells BM was flushed from femurs, tibias and hip bones of C57Bl/6 mice. Mononuclear cells were purified by gradient-centrifugation (Histopaque Ò 1083, Sigma-Aldrich, Munich, Germany) at 700 9 g for 20 min at room temperature. Lin À cells were selected by magnetic cell-sorting using lineage-specific antibodies: CD5, CD45R (B220), CD11b, Anti-Gr-1 (Ly-6G/C), 7-4 and Ter-119 (Miltenyi Biotech, Bergisch Gladbach, Germany). Briefly, cells were incubated with the biotin-labeled antibody cocktail for 20 min at 4°C, followed by the secondary antibody (antibiotin microbeads) for 20 min at 4°C. Antibody-labelled cells were run over a separation column and the lin À population collected from the flow through. Purified cells were cultivated in serum-free medium (StemSpan SFEM, StemCell Technologies, K€ oln, Germany), 10 ng mL À1 mSCF, 20 ng mL À1 mTHPO, 20 ng mL À1 mIGF2, 10 ng mL À1 hFGF-1, 2 mM glutamine and 1% penicillin/streptomycin. After pre-stimulation for 24-48 h, lin À cells were transduced twice on two following days with lentiviral vectors on Retronectin-coated wells (Takara-Clontech, Saint-Germain-en-Laye, France, 10 lg cm À2 , 24-well or 12-well plates, dependent on cell number), with a defined multiplicity of infection (MOI).
Hematopoietic differentiation in vitro
After transduction, cells were cultured in serum-free medium containing 50 ng mL À1 thrombopoietin (Thpo 
Bone marrow transplantation (BMT)
Animal experiments were carried out according to the German animal protection law and approved by the local ethical committee. C57Bl/6 mice were preconditioned with 10 Gy irradiation and Mpl-/-mice [29] with 8 Gy, before being transplanted with 5 9 10 5 cells. Cell infusion was performed via tail vein injection in 200 lL PBS. All mice were kept in the specified pathogen-free animal facilities of the Paul-Ehrlich-Institute, Langen, Germany.
Blood, spleen and BM cell analysis Blood samples were obtained by retro-orbital bleeding. For analysis of erythrocytes and platelets by flow cytometry, blood samples were diluted 1/2000 in PBS. Peripheral blood leukocytes were analyzed after erythrocyte lysis. Single cells from the spleen were isolated using a cell strainer.
Antibody-staining was performed in PBS, 2% FCS, 2 mM ethylenediaminetetraacetic acid (EDTA), using lineage-specific, conjugated antibodies: platelets (CD41), granulocytes (CD11b, GR1), T cells (CD3), B cells (B220), erythroid cells (Ter119, CD71) and hematopoietic stem and progenitor cells (HSPCs) (Sca-1, cKit, CD34, CD16/32). Antibodies were conjugated to fluorescein isothiocyanate (FITC), PE, APC, eFluor 450, Alexa700, PerCP-Cy5.5 or PE-Cy7 fluorochromes (Becton Dickinson, Heidelberg, Germany, eBioscience, or Roche Diagnostics, Mannheim, Germany). Dead cells were excluded by propidium iodide (PI) or 4 0 ,6-diamidino-2-phenylindole (DAPI) staining. Flow cytometry was carried out using the BD Accuri TM C6 or the LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
Cell sorting and mRNA detection
Cell sorting was performed on a BD AriaIII (BD Biosciences) directly into RNAzol preloaded tubes. Isolated RNA was reverse-transcribed with the RevertAid H-Minus Reverse-Transcriptase (Thermo Scientific, Waltham, MA, USA) and mRNA levels of Pf4, GpIba, Gp6, Gp9 and beta-actin as housekeeping gene detected with mouse-specific QuantiFast Probe Assays (Qiagen, Hilden, Germany). The TaqMan-based qPCR was performed on the StepOnePlus Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA) with the following cycling conditions: 95°-5 min/40 9 95°C-30 s/60°C-30 s.
Vector copy number detection (VCN)
The VCN was determined on genomic DNA purified from leukocytes, detecting the woodchuck hepatitis posttranscriptional regulatory element (wPRE) and the polypyrimidine tract-binding protein 2 (PTBP2) as an internal reference. Real-time TaqMan PCR (Life Technologies GmBH, Frankfurt, Germany) was performed using the StepOnePlus system (Applied Biosystems, Carlsbad, CA, USA) in triplicate. A plasmid standard harboring the sequences of the wPRE and PTPB2 was used for the quantification (primer information in Table S1 ).
Fluorescence microscopy of cultivated cells
Cells were placed or grown in lClear 96-well plates, fixed with 4% formaldehyde at 4°C for 12-48 h, and subjected to imaging using an Operetta (Perkin Elmer, Waltham, MA, USA) automated microscope in spinning disc-confocal mode. All pictures were acquired using the same settings and were adjusted similarly by the harmony software (Perkin Elmer) to a Gamma-value of 2 to enable visualization of low GFP signals.
Immunofluorescence staining on whole femora cryosections Femora of mice were isolated, fixed (4% paraformaldehyde, A3813, AppliChem, Darmstadt, Germany; 5 mM sucrose, S0389, Sigma-Aldrich), transferred into 10% sucrose-PBS and dehydrated using a graded sucrose series. Samples were then embedded in Cryo-Gel (39475237, Leica Biosystems, Wetzlar, Germany) and shock-frozen in liquid nitrogen. Frozen samples were stored at À80°C. Seven-micrometer-thick cryosections were generated using the CryoJane tape transfer system (Leica Biosystems) and probed with Alexa488-conjugated anti-GPIX [30] antibodies (56F8, 1.0 lg mL 
Results
Design of lentiviral vectors for megakaryocyte-specific expression
With the aim to develop lentiviral vectors that restrict expression to MKs and platelets, we introduced promoter fragments of MK-specific genes into third-generation, self-inactivating (SIN) lentiviral vectors in the internal position (Fig. 1A) . We selected a 794 bp/676 bp fragment of the h/mGP9 promoter [28] , a 726 bp fragment of the hGP6 promoter [27] and a shorter fragment of the hGP6 promoter of 351 bp [23] , a 1.2 kb of the murine (m)Pf4 [26] and 595 bp of the hGP1BA promoter [25] . As ubiquitously expressing control vectors, we analyzed the expression from the hPGK promoter in the lentiviral vector or the viral spleen focus forming enhancer/promoter (SFFV) in the context of the LTR-driven gammaretroviral vector. The latter is considered to have strong activity in hematopoietic cells [31] and was included in our in-vivo experiments, whereas the PGK promoter is known for achieving sufficient expression levels for correcting genetic hematological disorders [32, 33] . As a reporter, the enhanced green fluorescent protein (GFP) was expressed.
All vectors were produced with unconcentrated titers of 1 9 10 6 -1 9 10 7 transducing particles/ml. To investigate the specificity of expression, we transduced murine lin À BM cells, which were further differentiated into MKs and other hematopoietic cells in vitro, or transplanted into mice to assess in-vivo specificity of expression in blood cells and HSPCs (Fig. 1B) .
Expression from MK-specific lentiviral vectors in hematopoietic cells in vitro
Murine lin
À BM cells were transduced with MK-specific vectors, differentiated to MKs in vitro ( Figure S1 ) and analyzed for GFP fluorescence. Transduction efficiency was set to be below 20% to avoid multiple vector integrations per genome [34] ; therefore, not all MKs were transduced and GFP positive. Among the vectors, the mPf4 vector was the strongest, about 2.5 times more intense (measured by the mean fluorescent intensity (MFI)) than the hPGK control vector, followed by the hGP6 and hGP1BA-vectors, whereas the m/hGP9 vectors were the weakest ( Fig. 2A,B) . GFP intensity increased with polyploidisation, a measure of MK maturation, in cultures transduced with the MK-specific vectors, except for the hGP9 vector and the hPGK control vector (Fig. 2C ).
To assess the activity of the MK-specific lentiviral vectors in non-megakaryocytic cells, transduced lin À BM cells were differentiated in semi-solid medium for 8 days and analyzed for cell surface markers and GFP expression, identifying granulocytic (CD11b+/Gr1+), macrophage/monocytic (CD11b+/F4/80+) and erythroid (CD71/ Ter119) cells. The percentage of GFP-expressing cells in the MK-vector transduced and differentiated cells was in all cases lower than in the hPGK control (Fig. 2D, Figure S2 ). Promoter strength, as estimated by the MFI of GFP in positive cells, was always lower in cells transduced with MK-specific vectors than in cells transduced with the hPGK vector (Fig. 2E) . Furthermore, activity of the MK-specific vectors was investigated in non-hematopoietic primary cells and cell lines ( Figures S3, S4 ) and shown to be very low.
MK-specific lentiviral vectors confer high GFP expression in platelets
To analyze expression from the MK-specific lentiviral vectors in platelets, we next performed BM transplantations with transduced lin À BM cells into wild-type C57Bl/ 6 mice (cumulative MOI10, four to six recipients each).
As the murine and human GP9 vectors had the weakest expression levels between the MK vectors with the lowest specificity, we selected only the hGP9 vector to be tested in vivo. GFP expression was analyzed in the peripheral blood cells 20 weeks post-transplantation. Promoter strength, measured as the MFI of GFP-positive cells, was correlated with the expression from the hPGK vector, which was set to 1, referred to as relative expression. The highest expression in platelets was observed from the mPf4 vector, in respect of both percentage (Fig. 3A , B) and intensity (5.2AE3.4-fold higher than the hPGK vector, P = 0.009, Fig. 3D ). In platelets, the mPf4 vector was even stronger than the SFFV LTR vector (Fig. 3D) . Furthermore, expression from the hGP1BA, the hGP6 and hGP6s vectors was reasonably strong in platelets with the same relative expression as from the hPGK control vector (Fig. 3A,D) . Expression levels from the hGP9 vector, however, were low (Fig. 3A,D) , even though the median VCN in the transplanted mice was the highest within the MK-specific vector groups (Fig. 3F) , and importantly, the expression was not restricted to platelets (Fig. 3B,C) . There was also background promoter activity in leukocytes caused by the other MK-specific vectors, especially the mPf4 vector (29AE22% GFP-positive leukocytes, Fig. 3B,E) . Among the MK-specific vectors, the hGP6 vector was most restricted to platelets, with 8AE4.2-fold more GFP-positive platelets than leukocytes (Fig. 3B,C) and this specificity was maintained also with the shorter promoter-fragment hGP6s.
In the leukocyte fraction, most of the background activity of the MK-specific vectors resided in granulocytes, followed by B cells and T cells (Figures S5,S6 ). Expression in erythrocytes was almost undetectable from the MK-specific vectors, but also from the hPGK vector, possibly because of the long lifespan of erythrocytes, which may have lost the GFP protein (Fig. 3A) . Expression in erythroid progenitors isolated from the spleen demonstrated expression from the MK-specific vectors at the erythroblast stage, which declined with maturation. Among the vectors, expression in the erythroid lineage was the most pronounced from the hGP6 vector ( Figure S7 ). Third-generation self-inactivating lentiviral vectors were generated, expressing the reporter green fluorescent protein (GFP) from different megakaryocyte (MK)-specific promoters of indicated sizes in the internal position: murine platelet factor 4 promoter (mPf4), human glycoprotein Ib alpha promoter (hGP1BA), human glycoprotein 6 (hGP6) or the short version of hGP6, referred as hGP6s, as well the human glycoprotein 9 (GP9) promoter. As ubiquitously expressing control promoter, the human phosphoglycerate kinase promoter (hPGK) was used. U3 and U5, unique region 3 0 and 5 0 , respectively; R, repeat region; w, packaging signal; SD, splice donor; SA, splice acceptor; RRE, rev responsive element; cPPT, central polypurine tract; IP, internal promoter; wPre, woodchuck hepatitis virus post-transcriptional regulatory element. Promoters were verified by sequencing after insertion into the vector. (B) Workflow of in-vitro and in-vivo experiments. Lineage marker-negative cells from the bone marrow (BM) of C57Bl/6 wild-type mice were isolated, prestimulated for 24 h and transduced twice with lentiviral vectors. Cells were then either differentiated to MK in liquid cultures, plated into semi-solid differentiated medium for colony assays or transplanted into conditioned C57Bl/6 recipient mice. Reporter gene expression was measured by flow cytometry in the respective cell populations. [Color figure can be viewed at wileyonlinelibrary.com].
Expression from MK-specific lentiviral vectors in HSPCs
To investigate whether the new (hGP6, hGP6s, hGP9) or the mPf4 promoter fragments used in our lentiviral vectors had activity in HSPCs, we analyzed the percentage (Fig. 4, Figures S8-S10 ). The hGP6 vector showed the lowest activity in the HSPCs, with < 4% GFP-positive cells and~20% activity in the LSK cells, respectively (Fig. 4A, Figures S9,S10 ). The hGP6s vector was only slightly more active (< 10% positive LSK cells). In contrast, the mPf4 and hGP1BA vectors were both active in the HSPCs (10-70% GFPpositive cells in the respective HSPCs, Fig. 4A, Figures S9A,10) . When comparing the promoter strength (MFI) of the MK-specific promoters with the hPGK, the relative expression was in all cases lower (Fig. 4B) , whereas the relative expression from the SFFV promoter was 4.5AE2.3-fold higher compared with the hPGK promoter ( Figure S11 ).
To test whether the expression from the promoter fragments recapitulated the normal expression of the respective genes in the HSPCs, we measured RNA levels of murine Gp1ba, Gp6, Gp9 and Pf4 in sorted LSK, CMP, GMP and MEP populations of wild-type C57Bl/6 mice (Fig. 4C) . We confirmed substantial mRNA expression of murine Gp1ba and Gp9 in LSK, CMP and MEP cells (Fig. 4C ), which dropped with differentiation to the granulocytic/monocytic lineage (GMP). mRNA levels of Gp1ba and Gp9 were very similar, as would be expected by their function as subunits of the same receptor complex. mPf4 expression was 2.5-fold higher than Gp1ba expression in the LSK cells and increased substantially in the CMP (about 10-fold). In contrast, expression of murine Gp6 in HSPCs was almost null, which agrees with the low activity of the promoter fragment when introduced into the lentiviral vector in these cells in our experiments.
Expression in MKs in the BM in situ
To analyze specificity and expression strength from the MK-specific lentiviral vectors in the intact BM environment, we determined GFP expression in native cryosections of whole femora of mice transplanted with transduced BM cells. To visualize the BM structure, we performed immunostainings for MKs (GPIX) and blood vessels (endoglin, CD105). It has to be taken into account that not all cells in the transplant were gene marked and therefore GFP can only be detected in a subset of MKs.
In MKs, GFP was strongly expressed from the mPf4 vector (10AE4.5-fold) and also from the hGP1BA vector (7.4AE2.6-fold; Fig. 5A,B) , followed by the hGP6s vector (4AE2-fold) and the hGP6 vector (1.5AE0.7-fold, all values compared with the hPGK promoter). Expression from the hGP9 vector was similar to that from the hPGK vector (Fig. 5A,B) . Importantly, there was almost no fluorescent signal detected in non-MK cells when using the MK-specific vectors with minor background activity in myeloid cells ( Figure S12 ). The HSPC subset in which vector activity was demonstrated in our flow cytometric analysis only contributed < 1% of the BM cells and will not easily be visualized by microscopic analysis. Of note, expression from the viral SFFV promoter resulted in very strong GFP expression (15.4AE0.3-fold), which was not restricted to MKs.
Mpl expression from MK-specific lentiviral vectors improves Mpl-/-megakaryopoiesis
To address whether the new MK-specific lentiviral vectors allow the modification of megakaryopoiesis and platelet phenotype, we investigated the expression of the thrombopoietin receptor Mpl. We transduced lin-cells of Mpl-/-mice and differentiated MK in vitro or performed BM transplantations. Mpl-deficient mice have a known defect in megakaryocyte maturation and are thrombocytopenic [29] . In vitro, MK maturation and polyploidization were recovered by re-expression of Mpl, indicated by significantly more MKs with > 8n compared with Mpl-/-MKs (Fig. 6A,B, Figure S13 ). Mpl-/-mice transplanted with lin-BM cells transduced by the mPf4.Mpl and hGP6.Mpl vectors showed significantly elevated platelet counts compared with control mice transplanted with a GFP-encoding control vector (PGK.GFP, Fig. 6C,D) . In the BM, megakaryocyte maturation was improved with a higher number of polylobulated MKs ( Figure S14) . One of the mPf4.Mpl mice had a transient thrombocytosis 6 weeks after transplantation (Fig. 6E) . Two control groups of mice transplanted with lin-BM cells transduced with SFFV.Mpl and PGK.Mpl vectors developed severe erythrocytosis, leukocytosis (three/six mice) (Fig. 6E) , splenomegaly (0.6-2.5 g) and erythroid infiltrations in the liver ( Figure S15 ) and had to be killed 3 to 5 weeks after transplantation, demonstrating the need to restrict expression to MKs.
Discussion
In this study, we developed lentiviral vectors for specific expression in megakaryocytes and platelets by the use of promoter fragments of the MK-specific genes hGP1BA, hGP6, hGP9 and mPf4. We demonstrate that the hGP6 promoter in the lentiviral vector conferred the highest specificity, with adequate expression levels similar to those of the hPGK vector in platelets or even higher than those in MKs. The truncation of the hGP6 promoter to 350 bp (hGP6s) did not change its specificity or expression in MKs. The mPf4 vector had the strongest activity in platelets and MKs, followed by the hGP1BA vector; however, both showed also considerable off-target expression in leukocytes and HSPCs.
The hGP9 vector showed the weakest activity and no specificity although the promoter was described as MK specific. Table S2 . (C) mRNA levels relative to actin of the murine genes Pf4, Gp6, Gp1ba and Gp9 in the indicated populations of the HSPCs measured by RT-PCR (n = 3 independent cell sorts). Recent evidence has demonstrated a CD41+ population in the murine LSK cell pool. These cells were shown to be myeloid or MK biased. Gene expression analysis in these cells clearly demonstrated the expression of platelet factor 4 [18, 35, 36] . Also, the members of the GPIb-V-IX complex can be found in transcriptional profiles of HSCs [35, 37] . After inflammatory stimulation, the expression in HSCs is further up-regulated [20] . In combination with our own analysis, which also confirmed expression of GP1ba, Gp9 and Pf4 in the HSPCs of wild-type mice, the activity of the respective promoter fragments in this compartment was not completely unexpected. We detected unexpected high expression of Pf4 in CMP cells, which was also not recapitulated from the mPf4 promoter fragment. However, Gp6 was found not to be expressed in HSPCs and the GP6 promoter fragment used in our study showed only very low activity in these cells.
Because the MK-specific promoters share transcription factor binding sites (Ets, Fli1, Gata-1 and Sp1 [24, 27, 28, [38] [39] [40] ), it was surprising to see the differences in promoter performance when introduced into the lentiviral vectors. Especially the GP9 promoter fragment used in our study did not confer specificity. In the context of lentiviral gene transfer, only fragments of the cellular promoters can be used because of the size limitation of the vectors, and they will therefore reflect only to a certain extent the activity of the original cellular promoters, as regulatory elements may not be included. The hGP6 and hGP6s both contained the core sequence of 257 bp, including the described binding sites for Gata-1 and Ets1 (À176 and À45, respectively) [41] .
Finally, we demonstrate that expression of a functional protein, the Thpo receptor Mpl, by MK-specific vectors can alter MK and platelet phenotypes in vivo. The mPf4 vector exhibited superior effects because of its higher activity in MKs, but showed also transient adverse reactions in one mouse. In addition, the hematopoietic defect in Mpl-/-mice is more complex, with defects in HSCs and early MK progenitors [42] that may not be adequately corrected by MK-specific vectors as expression at earlier stages in hematopoietic development will be required. We further demonstrate the detrimental effects of ectopic Mpl expression, also from the ubiquitous hPGK promoter, which has a similar strength to the hGP6 vector. Uncontrolled expression of Mpl in hematopoiesis induced pathological erythroid hyperproliferation. Ectopic expression of transgenes in hematopoietic cells that are not the natural targets has been recognized to cause adverse reactions also in the context of other hematopoietic lineages ('phenotoxicity') [43] . For example, expression of subunits of the Nicotinamide adenine dinucleotide phosphate-oxidase complex for the treatment of chronic granulomatous disease or expression of galactocerebrosidase in gene therapy for globoid cell leukodystrophy causes HSC toxicity [44, 45] . Lymphocyte toxicity was shown after expression of Wiskott Aldrich Syndrome protein for the treatment of WiskottAldrich syndrome [46, 47] .
The new MK-specific lentiviral vectors will allow the modification of MKs and platelets by transplantation of transduced HSCs and can very flexibly be used to develop in-vivo mouse models by exchanging the transgenes or the genetic background of the target HSCs. In contrast to knockout mouse models, lentiviral gene transfer is especially well suited for the overexpression of genes but may also be employed for MK-specific knockdown or the delivery of Cre or other modifying enzymes. 
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